Citadel Advisors’s China Biologic Products Holdings, Inc. CBPO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-96,900
| Closed | -$11.5M | – | 15024 |
|
|
2021
Q1 | $11.5M | Buy |
96,900
+36,900
| +62% | +$4.36M | ﹤0.01% | 2777 |
|
|
2020
Q4 | $7.09M | Sell |
60,000
-71,800
| -54% | -$8.34M | ﹤0.01% | 3106 |
|
|
2020
Q3 | $14.6M | Sell |
131,800
-20,400
| -13% | -$2.19M | ﹤0.01% | 1862 |
|
|
2020
Q2 | $15.6M | Sell |
152,200
-6,200
| -4% | -$663K | 0.01% | 1737 |
|
|
2020
Q1 | $17.1M | Buy |
158,400
+57,200
| +57% | +$6.57M | 0.01% | 1358 |
|
|
2019
Q4 | $11.8M | Buy |
101,200
+84,400
| +502% | +$9.77M | 0.01% | 2029 |
|
|
2019
Q3 | $1.92M | Buy |
16,800
+4,500
| +37% | +$447K | ﹤0.01% | 4536 |
|
|
2019
Q2 | $1.17M | Sell |
12,300
-30,600
| -71% | -$2.88M | ﹤0.01% | 5444 |
|
|
2019
Q1 | $3.92M | Buy |
42,900
+23,800
| +125% | +$1.95M | ﹤0.01% | 3334 |
|
|
2018
Q4 | $1.45M | Buy |
19,100
+3,400
| +22% | +$250K | ﹤0.01% | 4690 |
|
|
2018
Q3 | $1.26M | Buy |
15,700
+7,700
| +96% | +$717K | ﹤0.01% | 5154 |
|
|
2018
Q2 | $795K | Buy |
+8,000
| New | +$691K | ﹤0.01% | 5604 |
|
|
2017
Q3 | – | Sell |
-2,800
| Closed | -$317K | – | 8502 |
|
|
2017
Q2 | $317K | Hold |
2,800
| – | – | ﹤0.01% | 5811 |
|
|
2017
Q1 | $280K | Buy |
2,800
+600
| +27% | +$64.1K | ﹤0.01% | 5977 |
|
|
2016
Q4 | $237K | Sell |
2,200
-4,400
| -67% | -$514K | ﹤0.01% | 6041 |
|
|
2016
Q3 | $822K | Buy |
+6,600
| New | +$779K | ﹤0.01% | 4087 |
|
Citadel Advisors's CBPO Position: Q2 2021 in Review
Citadel Advisors sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 318,196 shares — an estimated $37.7M sold.
Citadel Advisors first reported a position in CBPO in Q1 2014 and held it in 21 quarters. The position peaked at $37.7M in Q1 2021. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.
- Citadel Advisors reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
- Citadel Advisors sold 318,196 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $37.7M.
- Citadel Advisors first reported a position in China Biologic Products Holdings, Inc. in Q1 2014 and held it in 21 quarters.
- Citadel Advisors's China Biologic Products Holdings, Inc. position peaked at $37.7M in Q1 2021.
- 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.
Based on Citadel Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.